What is radioimunotherapy?

Radioimunotherapy is a technique of cancer treatment, which includes the subjugation of malignant tumors with high doses of radiation while saving near healthy body tissue. It is a relatively new form of treatment that is not widely used as the first or second defense against cancer. Non-Hodgkin's lymphoma greatly responds to radioimunotherapy in clinical trials and real medical practice, and most oncologists believe that treatment has a great promise to fight many other types of tumors.

The science of radioimunotherapy combines elements of traditional radiation treatment with new breakthroughs in immunology. Synthetic antibodies are produced in laboratories that are designed to act similarly to biological antibodies created by the immune system. When biological antibodies confront pathogens, they bind to proteins and block their activity. Instead of targeting bacteria and viruses with synthetic monoclonal antibodies, they bind to specific proteins on malignant tumor cells.

Each synthetic antibody containsThe exact amount of ionized radiation that can be emitted as soon as it connects to the tumor cells. Doctors first give relatively low -level radioactive antibodies to make sure they target the right cells and leave a healthy tissue in the room. Once the display and laboratory tests confirm that the antibodies work properly, the entire course of radioimunotherapy may begin. The number of treatment procedures that the patient needs depends on several factors, including his age, weight, overall health and specific type of cancer.

There are many potential advantages of using radioimunotherapy over other treatment options. Traditional chemotherapy and radiation are often effective in killing cancer cells, but healthy blood and tissue can also be affected. Radioimunotherapy eliminates most of the risks associated with chemotherapy, including the impact on white glitches of OOD cells and the functioning of the immune system. RadiationThe investigation exhibits malignant cells with radioactive materials, while the exposure is limited to healthy tissue with new techniques.

However, radioimunotherapy is not a perfect drug, and there are certainly risks that doctors must carefully consider. Treatment may increase the risk of human bleeding. If cancer in some way creates resistance to radiation after many doses, there may be no way to prevent the growth and spread of tumors. Many doctors and biochemists hope that current techniques will continue to improve and make radioimunotherapy the basis of initial cancer treatment. The ongoing research suggests that new innovations may be able to help erades brain tumors, leukemia, melanoma, ovarian cancer and prostate cancer except non-hodgkin lymphoma.